Incyte Corporation (NASDAQ:INCY) traded down 6.2% during mid-day trading on Monday following insider selling activity. The company traded as low as $98.72 and last traded at $98.95. 2,526,446 shares traded hands during mid-day trading, an increase of 31% from the average session volume of 1,934,999 shares. The stock had previously closed at $105.47.

Specifically, insider David W. Gryska sold 3,915 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul A. Friedman sold 28,507 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,569 shares of company stock valued at $15,652,970. 17.70% of the stock is owned by corporate insiders.

Several research analysts have commented on the company. J P Morgan Chase & Co restated a “buy” rating and issued a $149.00 target price on shares of Incyte Corporation in a research note on Thursday, August 31st. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating and issued a $135.00 price target on shares of Incyte Corporation in a report on Thursday, August 31st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $148.00 price target on shares of Incyte Corporation in a report on Thursday, July 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 price target (down previously from $172.00) on shares of Incyte Corporation in a report on Monday, September 11th. Finally, Raymond James Financial, Inc. raised Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price target on the stock in a report on Monday, September 11th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $144.98.

The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same period last year, the company earned $0.19 EPS. Incyte Corporation’s revenue for the quarter was up 41.6% compared to the same quarter last year. equities research analysts forecast that Incyte Corporation will post -1.33 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of INCY. Vanguard Group Inc. grew its position in shares of Incyte Corporation by 11.1% in the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after buying an additional 1,709,685 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in shares of Incyte Corporation in the 3rd quarter worth approximately $125,065,000. Janus Henderson Group PLC grew its position in shares of Incyte Corporation by 4,570.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock worth $131,622,000 after buying an additional 1,022,979 shares during the last quarter. Old Mutual Global Investors UK Ltd. grew its position in shares of Incyte Corporation by 374.4% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock worth $108,605,000 after buying an additional 734,235 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Incyte Corporation by 64.1% in the 2nd quarter. Jennison Associates LLC now owns 1,313,982 shares of the biopharmaceutical company’s stock worth $165,443,000 after buying an additional 513,423 shares during the last quarter. Hedge funds and other institutional investors own 89.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/20/incyte-corporation-incy-shares-down-6-2-following-insider-selling.html.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.